Piracetam for Treatment of Cocaine Addiction, Phase II - 4

This study has been withdrawn prior to enrollment.
Sponsor:
Collaborator:
Information provided by:
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00000199
First received: September 20, 1999
Last updated: July 25, 2013
Last verified: July 2013
  Purpose

The purpose of this study is to follow patients in Phase I of an inpatient study in an eight week open label assessment of piracetam in an outpatient treatment program.


Condition Intervention Phase
Cocaine-Related Disorders
Drug: Piracetam
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Piracetam for Treatment of Cocaine Addiction, Phase II

Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • Drug use
  • Adverse effects
  • Clinical status

Enrollment: 0
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000199

Locations
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Sponsors and Collaborators
University of Pennsylvania
Investigators
Principal Investigator: Kyle Kampman, M.D. University of Pennsylvania
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000199     History of Changes
Other Study ID Numbers: NIDA-00238-4, K20DA000238, K02-00238-4
Study First Received: September 20, 1999
Last Updated: July 25, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Piracetam
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Nootropic Agents

ClinicalTrials.gov processed this record on April 15, 2014